Real-world safety and 1-year effectiveness of dupilumab in Japanese patients with atopic dermatitis: An interim analysis of ongoing regulatory post-marketing surveillance

被引：0
|
作者：
Fujita, Hiroyuki [1 ]
Suzuki, Katsuhisa [1 ]
Arima, Kazuhiko [1 ]
Saeki, Hidehisa [2 ]
机构：
[1] Sanofi KK, Tokyo, Japan
[2] Nippon Med Sch, Tokyo, Japan
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
32501
引用
收藏
页码：AB200 / AB200
页数：1
相关论文
共 50 条
  • [1] Safety and effectiveness of dupilumab in the real-world treatment of atopic dermatitis in Japan: 1-year interim analysis from a post-marketing surveillance
    Saeki, Hidehisa
    Fujita, Hiroyuki
    Suzuki, Katsuhisa
    Arima, Kazuhiko
    JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY, 2023, 6 (03) : 78 - 87
  • [2] Real-world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post-marketing surveillance in Japan
    Takayama, Koichi
    Kojima, Ai
    Honda, Chikara
    Nakayama, Masahiro
    Kanemata, Satomi
    Endo, Toshimitsu
    Muro, Kei
    CANCER MEDICINE, 2024, 13 (09):
  • [3] Real-world safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 401 Japanese patients: results from an interim analysis of post-marketing surveillance
    Tachibana, Yosuke
    Takasaki, Sakura
    Hoshino, Misuzu
    Makioka, Haruki
    Jin, Mingshou
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2024, 134 (02) : 153 - 162
  • [4] Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study
    Hide, Michihiro
    Fukunaga, Atsushi
    Suzuki, Takayuki
    Nakamura, Noriko
    Kimura, Mine
    Sasajima, Takayoshi
    Kiriyama, Junna
    Igarashi, Atsuyuki
    ALLERGOLOGY INTERNATIONAL, 2023, 72 (02) : 286 - 296
  • [5] Real-world effectiveness of eculizumab in generalized myasthenia gravis in Japan: 1-year post-marketing surveillance data
    Murai, Hiroyuki
    Suzuki, Shigeaki
    Fukamizu, Yuji
    Osawa, Takehiko
    Kikui, Hidekazu
    Utsugisawa, Kimiaki
    NEUROLOGY, 2022, 98 (18)
  • [6] Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan
    Hayashi, Nobukazu
    Hayama, Koremasa
    Takahashi, Kenzo
    Kurokawa, Ichiro
    Okazaki, Masateru
    Kashiwagi, Tomoko
    Iwashita, Eri
    Terui, Tadashi
    JOURNAL OF DERMATOLOGY, 2022, 49 (04): : 411 - 421
  • [7] Real-world safety of nusinersen in Japan: results from an interim analysis of a post-marketing surveillance and safety database
    Wataya, Takafumi
    Takasaki, Sakura
    Hoshino, Misuzu
    Makioka, Haruki
    Nakamura, Genshu
    Matsuda, Naoto
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2023, 133 (08) : 851 - 863
  • [8] Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance
    Murai, Hiroyuki
    Suzuki, Shigeaki
    Hasebe, Miki
    Fukamizu, Yuji
    Rodrigues, Ema
    Utsugisawa, Kimiaki
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [9] Safety and effectiveness of dupilumab in the treatment of atopic dermatitis in Japanese patients: the first interim analysis report from postmarketing surveillance
    Fujita, H.
    Suzuki, K.
    Arima, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E142 - E142
  • [10] Real-world safety and effectiveness of adalimumab in patients with pyoderma gangrenosum: Interim analysis of a post-marketing observational study in Japan
    Yamamoto, Toshiyuki
    Yamanaka, Keiichi
    Yamasaki, Kenshi
    Isaji, Hisaaki
    Matsubara, Naoko
    Hozawa, Hiroyuki
    Kawakami, Tamihiro
    JOURNAL OF DERMATOLOGY, 2025, 52 (02): : 270 - 280
12345